Changes in Muscle Strength, Inflammatory Markers, and Body Composition in Response to Alternate Day Fasting Combined With Krill Oil Supplementation in Adults With Overweight and Obesity

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this double-blind, randomised, controlled trial is to determine the effects of LC n-3 PUFAs supplementation on changes in body composition and muscle strength during body weight loss and body weight maintenance among healthy adults living with overweight and obesity. The main research questions: * Is supplementation with LC n-3 PUFAs during dietary weight loss intervention (alternative-day fasting) attenuate the reduction in fat-free mass and muscle strength? * Is supplementation with LC n-3 PUFAs during dietary weight loss intervention (alternative-day fasting) provide additional impact on appetite related hormones (Acylated ghrelin, GLP-1, and PYY) and cardiometabolic risk factors (Post prandial inflammatory markers and Triglycerides)? Participants will be randomly assigned to a PLACEBO (Mix-vegetables oil) or LC n-3 PUFAs group (krill oil) (1:1 basis). Both groups will follow a dietary weight loss intervention (Alternate-day fasting). The study will last for 20 weeks that divided into 3 phases: four weeks of the preparation phase, eight weeks of body weight loss phase (Alternate Day Fasting), followed by eight weeks of body weight maintenance phase (regular diet).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 65
Healthy Volunteers: t
View:

• Healthy (male/female)

• body mass index (BMI) of 25 - 39.9 kg/m2

• Aged between 25 and 65 years

• stable body weight for at least three months

Locations
Other Locations
United Kingdom
University of Glasgow, New Lister Building
RECRUITING
Glasgow
Contact Information
Primary
Dalia Malkova, PhD
Dalia.Malkova@glasgow.ac.uk
07753433971
Backup
Mansour Alblaji
m.alblaji.1@research.gla.ac.uk
07310647742
Time Frame
Start Date: 2022-03-28
Estimated Completion Date: 2024-11-20
Participants
Target number of participants: 50
Treatments
Experimental: Krill oil capsules (LC n-3 PUFAs)
4 g/day krill oil (SuperbaBoostTM), with each 1g capsule containing 191mg EPA, 94mg DHA and 78mg choline.
Placebo_comparator: Vegetable oil capsules
4g/day of mixed vegetable oil (a mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
Related Therapeutic Areas
Sponsors
Leads: University of Glasgow

This content was sourced from clinicaltrials.gov

Similar Clinical Trials